Regeneron beats quarterly results estimates on strong Dupixent demand

Sanofi SA

29/04/2026 12:41

April 29 (Reuters) - Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for first-quarter profit and revenue on Wednesday, helped by strong demand for its eczema drug, Dupixent, and cancer drug, Libtayo, offsetting competitive pressures faced by eye drug Eylea.

The company has been relying on Dupixent, which it co-develops with French drugmaker Sanofi SASY.PA, to offset pressure in its eye-drug business, where its blockbuster drug Eylea has faced competition from cheaper versions and rival treatments such as Roche's ROPC.S Vabysmo.

Regeneron is trying to switch more patients to Eylea HD, the higher-dose version of the drug.

Quarterly sales for Dupixent - the highest prescribed biologic by dermatologists and pulmonologists in the U.S. - recorded by Sanofi rose 33% to $4.88 billion, above analysts' estimates of $4.59 billion, according to LSEG data.

Total Eylea sales, including the high dose, for the quarter fell 10% to $941 million. Eylea HD sales rose 52% to $468 million.

Last year, the U.S. Food and Drug Administration declined to approve a pre-filled syringe version of Eylea HD due to issues at contract manufacturer, Catalent's Indiana filling facility, now owned by Novo Holdings.

Regeneron said the regulator did not act by its April 2026 target date on the company's application for a second contract manufacturer. The company anticipates a regulatory decision during the second quarter.

Sales of Regeneron's cancer treatment, Libtayo rose 54% to $438 million.

Total quarterly revenue came in at $3.61 billion, above analysts' expectations of $3.49 billion.

The company also said its board authorized a new $3 billion share repurchase program.

Last week, Regeneron struck a pricing deal with the U.S. government under which it said it would lower some Medicaid prices and sell its cholesterol drug, Praluent, at a lower price through a new online platform, TrumpRx.gov.

The Tarrytown, New York-based company posted a first-quarter adjusted profit of $9.47 per share, above analysts' estimate of $8.94.

 (Reporting by Kunal Das and Puyaan Singh in Bengaluru; Editing by Maju Samuel)

 ((Kunal.Das2@thomsonreuters.com;))